anti-tumor necrosis factor alpha triplex-forming oligonucleotide

An **anti-tumor necrosis factor alpha triplex-forming oligonucleotide (anti-TNF-α TFO)** is a synthetic oligonucleotide designed to bind specifically to the major groove of double-stranded DNA at the promoter or coding region of the tumor necrosis factor alpha (TNF-α) gene via a triplex helix formation, thereby inhibiting TNF-α gene transcription[1][3][7]. TNF-α is a pro-inflammatory cytokine crucial in the pathogenesis of many inflammatory and autoimmune diseases. This molecule is engineered as a therapeutic to silence TNF-α gene expression at the DNA level ("antigene" approach), as opposed to antisense or siRNA technologies which target mRNA. Anti-TNF-α TFOs have shown superior efficacy compared to siRNA in preclinical animal models of arthritis and suppressed synovitis, cartilage, and bone destruction[1][7]. Development is preclinical with published proof-of-concept data but **not yet in clinical use**. The technology has generally been explored in academic settings; there are no known commercial developers or manufacturers[1][3][7].

Other names

anti-TNF-α triplex-forming oligonucleotideanti-TNF-α TFOanti-TNF alpha TFOanti-tumor necrosis factor alpha TFO